Analysis of Plasma Orexin Levels in Pedıatrıc Migraine Patients: A Prospectıve Controlled Clinical Study

Year 2021, Volume: 7 Issue: 2, 269 - 275, 31.08.2021

Hülya İnce , Ömer Faruk Aydın , Hasan Alaçam , Erhan Çetin Çetinoğlu

https://doi.org/10.19127/mbsjohs.908941

Abstract

Objective: Migraine is the most common primary headache disorder in children. However, its pathogenetic mechanisms are not fully understood. Researchers focused on Orexin A (a neuropeptide with anti-nociceptive effects) and Orexin B (a neuropeptide with pro-nociceptive effects), but the literature is scarce in terms of studies investigating the plasma levels of these neuropeptides in pediatric migraine patients. We aimed to compare the plasma levels of orexins between pediatric migraine patients and healthy controls

Methods: Children aged between 5 and 18 who were under diagnostic evaluation for and diagnosed with migraine in Ondokuz Mayıs University, Department of Pediatric Neurology between December 2018 and December 2019, constituted the target population. All study group patients (Group 1) were diagnosed with migraine according to IHS 2004 criteria. The control group (Group 2) consisted of healthy children. Data including age, gender, and presence or absence of aura were recorded. Two blood samples were taken from the patients in Group 1. The first sample was withdrawn during a non-attack period, and the second sample was withdrawn during the initial migraine attack. Only one blood sampling was done in the control group. Plasma Orexin A and Orexin B levels were analyzed by radioimmunoassay and compared between Group 1 and Group 2 during non-attack and attack periods. Also, intra-group comparative analyses were performed. Non-parametric tests were used for statistical analysis.

Results: This study included 98 patients, 52 children with migraine (Group 1), and 46 healthy children (Group 2). Mean patient age was 12,5±3,1 year in Group 1 and 12,3±3,4 years in Group 2. There was no difference between patient groups in terms of gender (p=0,103) and age (p=0,734). Plasma Orexin A levels of the migraine patients were higher than control group participants during the non-attack period, while Orexin B levels of the migraine patients were higher than migraine patients during the attack period. The mean plasma Orexin A level was significantly higher during the non-attack period than the attack period (p=0,002). The mean plasma Orexin B level was significantly higher during the attack than in the non-attack period (p=0,002). The presence of aura did not impact plasma orexin levels during both attack and non-attack periods.

Conclusions: The plasma level of Orexin A is elevated in migraine patients, probably as a response to nociceptive signals, and migraine attack is associated with elevated plasma Orexin B levels. Targeting the orexinergic system seems like a reasonable approach to improving the treatment of migraine disease.

Keywords

migraine, orexin, pediatric, headache, treatment, children

References

• 1. Oleson J. The international classification of headache disorders. Cephalalgia. 2004; 24 (suppl):9-160.
• 2. Winner P, Martinez W, Mate L, Bello L. Classification of pediatric migraine: proposed revisions to the IHS criteria. Headache. 1995;35(7):407-410. doi:10.1111/j.1526-4610.1995.hed3507407.x
• 3. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1994;309(6957):765-769. doi:10.1136/bmj.309.6957.765
• 4. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin. 2009;27(2):321-334. doi:10.1016/j.ncl.2008.11.011
• 5. Goldstein M, Chen TC. The epidemiology of disabling headache. Adv Neurol. 1982;33:377-390.
• 6. Jain S, Malinowski M, Chopra P, Varshney V, Deer TR. Intrathecal drug delivery for pain management: recent advances and future developments. Expert Opin Drug Deliv. 2019;16(8):815-822. doi:10.1080/17425247.2019.1642870
• 7. O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015;17(1):326. doi:10.1007/s11940-014-0326-1 8. Tajti J, Szok D, Majláth Z, Tuka B, Csáti A, Vécsei L. Migraine and neuropeptides [published correction appears in Neuropeptides. 2016 Dec;60:91]. Neuropeptides. 2015;52:19-30. doi:10.1016/j.npep.2015.03.006
• 9. Sarchielli P, Rainero I, Coppola R, Rossi C, Mancini Ml, Pinessi L, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28(7):714-722. doi:10.1111/j.1468-2982.2008.01566.x
• 10. Caproni S, Corbelli I, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. Cephalalgia. 2011;31(5):543-549. doi:10.1177/0333102410392605
• 11. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache. 2007;47(6):951-962. doi:10.1111/j.1526-4610.2007.00842.x
• 12. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005;315(3):1380-1385. doi:10.1124/jpet.105.090951
• 13. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004;109(3):367-378. doi:10.1016/j.pain.2004.02.005
• 14. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006;24(10):2825-2833. doi:10.1111/j.1460-9568.2006.05168.x
• 15. Rainero I, Rubino E, Gallone S, Fenoglio P, Picci LR, Giobbe L, et al. Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain. 2011;12(2):193-199. doi:10.1007/s10194-011-0314-8
• 16. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570-584. Published 2011 Sep 20. doi:10.1038/nrn3057
• 17. Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015;74:137-143. doi:10.1016/j.nbd.2014.10.022
• 18. Cady RJ, Denson JE, Sullivan LQ, Durham PL. Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization. Neuroscience. 2014;269:79-92. doi:10.1016/j.neuroscience.2014.03.043
• 19. Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2015;35(5):379-388. doi:10.1177/0333102414544979
• 20. Bigal ME, Hargreaves RJ. Why does sleep stop migraine? [published correction appears in Curr Pain Headache Rep. 2014 Jan;18(1):390]. Curr Pain Headache Rep. 2013;17(10):369. doi:10.1007/s11916-013-0369-0
• 21. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-1675. doi:10.1016/S0140-6736(01)06711-3
• 22. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. doi:10.1212/01.wnl.0000252808.97649.21
• 23. Ravid S. Migraine & paediatric obesity: a plausible link?. Indian J Med Res. 2014;139(3):343-348.
• 24. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia. 1996;16(5):310-316. doi:10.1046/j.1468-2982.1996.1605310.x 25. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193-196. doi:10.1002/ana.410230214